F
Gerald Bronfman Centre
for Clinical Research in Oncology
Clinical Research Program
 
Brain Gastro-Intestinal Gynecologic Hematologic Lung Myeloma Solid Tumors
Breast Genito-Urinary Head & Neck Terminated
Studies
Melanoma Sarcoma Symptom Control/
Supportive Care

Page updated:  June 17, 2013

Hematologic
Site ID Study Title Status
AML McG 0528

MGI Pharma Inc.
DACO-016

Randomized Phase 3 Trial of Decitabine versus Patient’s Choice with Physician’s Advice of either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients with Newly Diagnosed Acute Myeloid Leukemia

Principal Investigator: Dr John Storring

Closed
AML McG 1222 A Phase III Randomised, Double-Blind, Controlled, Parallel Group Study Of Intravenous Volasertib In Combination With Subcutaneous Low-Dose Cytarabine Vs. Placebo + Low-Dose Cytarabine In Patients ≥ 65 Years With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible For Intensive Remission Induction Therapy

Principal Investigator: Dr John Storring

Pending
 IRB Approva
l
ALL NCIC CTG AL.5 Adult ALL Trial Adult ALL Trial

Principal Investigator: Dr John Storring

Closed

 

AML NCIC CTG ALC.1 A Phase III Study of the Addition of Gemtuzumab Ozogamicin (Mylotarg) during Induction Therapy versus Standard Induction with Daunomycin and Cytosine Arabinoside Followed by Consolidation and Subsequent Randomization to Post-Consolidation Therapy with Gemtuzumab Ozogamicin (Mylotarg) or no Additional Therapy for Patients Under Age 56 with Previously Untreated De Novo Acute Myeloid Leukemia (AML)

Principal Investigator: Dr John Storring

Closed
AML

 

NCIC CTG ALC.2

Phase III Randomized, Double-Blind Study Of Induction (Daunorubicin / Cytarabine) And Consolidation (High-Dose Cytarabine) Chemotherapy + Midstaurin (PKC412) (IND 3 101261) Or Placebo In Newly Diagnose Patients < 60 Years Of Age With FLT3 Mutated Acute Myeloid Leukemia (AML)

Principal Investigator: Dr John Storring

Closed

RVH   JGH

MGH          

AML NCIC CTG IND.186 A Phase I/II Study of Sorafenib (BAY 43-9006) in Combination with Low Dose ARA-C (Cytarabine) in Elderly Patients with AML or High-Risk MDS

Principal Investigator: Dr Sarit Assouline

Closed
CLL McG 1232

Merck
MK-7965-012-02
A Study To Evaluate The Efficacy And Safety Of Dinaciclib Or Ofatumumab In Subjects With Refractory Chronic Lymphocytic Leukemia (CLL)

Principal Investigator: Dr John Storring

Pending
 IRB Approva
l
CLL

 

NCIC CTG CL.3 A Randomized Phase II Study Of Three Fludarabine/ Antibody Combinations For Patients With Symptomatic Previously Untreated Chronic Lymphocytic Leukemia

Principal Investigator: Dr Sarit Assouline

Closed

RVH  JGH
CLL/SLL McG 1230

Janssen Research & Development LLC

“HELIOS” trial
Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination with Bendamustine and Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma.  

                                 Principal Investigator: Dr Sarit Assouline
Active

JGH

CML McG 0011

Novartis
CSTI571 0106
 “IRIS”

A Phase III Study of STI571 Versus Interferon-a (IFN-a) Combined with Cytarabine (ARA-C) in Patients with Newly Diagnosed Previously Untreated Philadelphia Chromosome Positive (PH+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

Principal Investigator: Dr Chaim Shustik

Closed
CML McG 0910

Novartis
CAMN107A2405
An Open-Label, Randomized Study of Nilotinib vs. Standard Imatinib (400/600 mg QD) Comparing the Kinetics of Complete Molecular Response for CML-CP Patients with Evidence of Persistent Leukemia by
RQ-PCR

Principal Investigator: Dr Pierre Laneuville

TERMINATED
 
CML

 

McG 1009

Novartis
CAMN107
AUS17

An Exploratory Trial to Assess The Improvement Of Chronic Low-Grade Non-Hematologic Adverse Events Experienced By Patients With Philadelphia Chromosome Positive (PH+) Chronic Myelogenous Leukemia In Chronic Phase (CML-CP) Treated With Imatinib When Switched To Nilotinib Treatment

Principal Investigator: Dr Pierre Laneuville

Closed

RVH  JGH

 

CML

 

McG 1026

ARIAD
AP24534-10-201

 

A Pivotal Phase 2 Trial of Ponatinib (AP24534) in Patients with Refractory Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia  

Principal Investigator: Dr Pierre Laneuville

 

Closed
RVH
only

CML McG 1130

Lundbeck Canada
14293A
An Open-Label Expanded Access Trial for Bendamustine HCl in Patients with Indolent Non-Hodgkin’s Lymphoma that has Progressed during or Following Treatment with a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia (BEND-ACT)  

Principal Investigator: Dr Chaim Shustik

Closed

JGH     RVH

  SMH

CML McG 1221

ARIAD Pharmaceuticals
AP24534-12-301

A Phase 3 Randomized, Open-Label Study Of Ponatinib Versus Imatinib In Adult Patients With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase 

Principal Investigator: Dr Sarit Assouline

Active

RVH    JGH
CML or PCPALL McG 0737

BMS
CA180-188

Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects who are Experiencing Clinical Benefit on Current START Protocols:  Long Term Safety and Efficacy Analysis

Principal Investigator: Dr Pierre Laneuville

Closed
CML or PCPALL McG 0924

Merck Frosst
098

A Multicenter Phase Ib Trial to Determine Whether a Gene Expression Signature Changes in Response to Treatment with Bcr-Abl Inhibitors in Patients with Blast Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphocytic Leukemia

Principal Investigator: Dr Pierre Laneuville

Closed
Lymphoma McG 0827

PRELUDE: A Phase 3 Clinical Study to investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin

Principal Investigator: Dr Sarit Assouline

Closed
Lymphoma
(T-Cell)
McG 0936

Topo Target
PDX101-CLN-19
A Multicenter, Open-Label Trial of Belonistat in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

Principal Investigator: Dr Sarit Assouline

Closed
Lymphoma
(T-Cell)
McG 1218

Millennium Pharmaceuticals
C14012

A Phase 3, Randomized, Two-Arm, Open-Label, Multicenter, International Trial of Alisertib (MLN8237) or Investigator’s Choice (Selected Single Agent) in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

Principal Investigator: Dr Sarit Assouline

Active

RVH    JGH
Lymphoma

 

McG 0932

Novartis
CRAD0001N2301

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase III Study Of RAD001 Adjuvant Therapy In Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-Line Rituximab-Chemotherapy

Principal Investigator: Dr Pierre Laneuville

Active

RVH only

Lymphoma NCIC CTG IND.172 A Phase II Study of Bortezomib and Gemcitabine in Patients with Relapsed Mantle Cell Lymphoma

Principal Investigator: Dr Sarit Assouline

Closed
 
Lymphoma NCIC CTG IND.194 A Phase II Study of AT7519M, a CDK Inhibitor, in Patients with Relapsed Mantle Cell Lymphoma
 

                                 Principal Investigator: Dr Sarit Assouline
Active

JGH   
Lymphoma
(DLBCL)
McG 1113 A Phase III, Multicenter, Open-Label, Randomized Trial Comparing The Efficacy Of Ga101 (Ro5072759) In Combination With Chop (G-Chop) Versus Rituximab And Chop (R-Chop) In Previously Untreated Patients With CD20-Positive Diffuse Large B-Cell Lymphoma (DLBCL).

Principal Investigator: Dr Nathalie Johnson

Active

JGH

NHL NCIC CTG LY.13 A Multi-Centre Phase II Trial Investigating the Efficacy and Tolerability of Bortezomib Added to Cyclophosphamide, Vincristine, Prednisone, and Rituximab (Bcvp-R) for Patients with Untreated Advanced Stage Follicular Non-Hodgkin’s Lymphoma

Principal Investigator: Dr Chaim Shustik

Closed
HL NCIC HD.7

A Randomized Phase III Trial of ABVD Versus Stanford V +/- Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin’s Disease with 0-2 Risk Factors

Principal Investigator: Dr Pierre Laneuville

Closed
Myelodysplastic McG 0903

Amgen
20060198
A Randomized, Double-Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Thrombocytopenia in Subjects with Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Principal Investigator: Dr John Storring

Closed
Myelodysplastic  McG 1024

Amgen
20060197
An Open Label Extension Study Evaluating the Safety in Long Term Dosing of Romiplostim (formerly AMG 531) in Thrombocytopenic Subjects with Myelodysplastic Syndrome (MDS)

Principal Investigator: Dr John Storring

Closed

RVH only

Myelodysplastic McG 1121 A Phase 3, Multicenter, Randomized, Double-Blind,Placebo-Controlled, Parallel-Group Study To Compare The Efficacy And Safety Of Lenalidomide (Revlimid®) Versus Placebo In Subjects With Transfusion-Dependent Anemia Due To IPSS Low Or Intermediate-1 Risk Myelodysplastic Syndromes Without Deletion 5Q[31] And Unresponsive Or Refractory To Erythropoiesis-Stimulating Agents
                                  
                                   
Principal Investigator: Dr John Storring
Active

RVH and SMH

NHL McG 1130

Lundbeck Canada Inc.

An Open-Label Expanded Access Trial for Bendamustine HCl in Patients with Indolent Non-Hodgkin’s Lymphoma that has Progressed during or Following Treatment with a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia (BEND-ACT)

Principal Investigator: Dr Chaim Shustik

Closed

JGH, RVH and SMH

PMF / PPV-MF / PET-MF McG 1203

Novartis
CINC424A2401 (JUMP)
AN OPEN-LABEL, MULTICENTER, EXPANDED ACCESS STUDY OF INC424 FOR PATIENTS WITH PRIMARY MYELOFIBROSIS (PMF) OR POST POLYCYTHEMIA MYELOFIBROSIS (PPV MF) OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF)

                                Principal Investigator: Dr Jaroslav Prchal
Closed
PMF / PPV-MF / PET-MF with Splenomegaly McG 1204

sanofi-Aventis
EFC12153
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled 3-Arm Study Of SAR302503 In Patients With Intermediate-2 Or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Or Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly

                                Principal Investigator: Dr Shireen Sirhan

Closed

JGH and SMH

Page updated:  June 17, 2013